<DOC>
	<DOCNO>NCT00812266</DOCNO>
	<brief_summary>Randomised trial compare standard chemotherapy carboplatin etoposide combination topotecan cisplatin patient inoperable lung cancer small cell type .</brief_summary>
	<brief_title>Topotecan Cisplatin Versus Etoposide Carboplatin 1st Line Treatment Patients With Small Cell Lung Cancer Extensive Disease ( SCLC-ED )</brief_title>
	<detailed_description>Fase III , multicenter randomise trial compare six cycle carboplatin etoposide six cycle topotecan cisplatin patient extensive stage small cell lung cancer PS 0-3</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>Histologically confirm SCLC Extensive stage No prior chemotherapy WHO PS 03 Adequate organ function ( liver , kidney ) Adequate hematology ( bone marrow ) Informed consent PS 4 Inadequate organ function Uncontrolled infection Concomitant major medical contraindication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>SCLC</keyword>
	<keyword>Extensive disease</keyword>
	<keyword>topotecan</keyword>
</DOC>